KRAS and large cell neuroendocrine carcinoma: Miyoshi and colleagues analyzed the genomic profiles of both LCNEC and SCLC, and they showed that the profile was not so different, with a lower alteration of RB1 in LCNEC and alterations in the PI3K/AKT/mTOR pathway (15%), KRAS (6%), FGFR1 (5%), and EGFR (1%), suggesting potential targeted therapies for this challenging type of lung cancer.